Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.57 |
| ▸ | TPO | P07202 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | EIF4EBP1 | Q13541 | 5/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | ARF6 | P62330 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14936450 | 0.93 | MPO (0.57) | MPOTPOPTGDR2MAPK1GAA | |
| SCHEMBL18205755 | 0.88 | MPO (0.54) | MPOTPOPTGDR2MAPK1GAA | |
| SCHEMBL15366347 | 0.87 | MPO (0.56) | MPOTPOPTGDR2MAPTEIF4EBP1 | |
| Hydrochloric Acid SCHEMBL18205711 | 0.87 | MPO (0.53) | MPOTPOPTGDR2MAPK1GAA | |
| SCHEMBL14947171 | 0.87 | MPO (0.76) | MPOTPOPTGDR2MAPK1GAA | |
| SCHEMBL14936386 | 0.86 | MPO (0.54) | MPOTPOPTGDR2MAPK1GAA | |
| SCHEMBL14936679 | 0.86 | MPO (0.57) | MPOTPOMAPK1GAATP53 | |
| Hydrochloric Acid SCHEMBL14936241 | 0.85 | MPO (0.56) | MPOTPOMAPK1GAATP53 | |
| SCHEMBL14947170 | 0.85 | MPO (0.59) | MPOTPOPTGDR2MAPK1TP53 | |
| SCHEMBL14946958 | 0.85 | MPO (0.73) | MPOTPOMAPK1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170275257-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275257-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9771332-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771332-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2016178113-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326121-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326121-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. | 2016-11-10 | — | — | US | disclosed |
| US-8841314-B2 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123230-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885PTGDR2 2008/4885 |
| US-20160326121-A1 | 2-THIOPYRIMIDINONES | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885PTGDR2 2674/4885 |
| US-20170275257-A1 | 2-THIOPYRIMIDINONES | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885PTGDR2 2674/4885 |
| US-20130296351-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885PTGDR2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.